Managing drug infusion reactions: focus on cetuximab monoclonal antibody therapy.
نویسنده
چکیده
June 2008 • Volume 12, Number 3 • Clinical Journal of Oncology Nursing Gail Wilkes, RN, MS, AOCN®, ANP, is an oncology nurse educator at Boston Medical Center in Massachusetts. Wilkes is on the speakers bureau for Bristol-Myers Squibb Oncology. Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.
منابع مشابه
Cetuximab-associated infusion reactions: pathology and management.
Cetuximab (Erbitux), a chimeric antiepidermal growth factor receptor monoclonal antibody currently used to treat metastatic colorectal cancer, is in clinical development for several other solid tumors. Although cutaneous manifestations are the most common toxicities associated with cetuximab, they are rarely life-threatening. Cetuximab-related infusion reactions are less common, but they may be...
متن کاملمقایسه تأثیر شیمی‌درمانی استاندارد و اثر ترکیبی آن با Cetuximab بر میزان بقاء در مبتلایان به سرطان پیشرفته کولون
Background and Aim: Recent advances in molecular and cellular biology and the importance of Epidermal growth factor receptor(EGFR) in the development and progression of many solid malignancies such as Colorectal Cancer (CRC) and non- small cell lung cancer have allowed rapid advances in rational drug design and targeted therapies for malignancies.Cetuximab or Erbitux, an IgG1 monoclonal antib...
متن کاملCetuximab: adverse event profile and recommendations for toxicity management.
Cetuximab (Erbitux, IMC-C225, ImClone Systems Incorporated, New York, NY) is a monoclonal antibody targeted to the epidermal growth factor receptor. Expression of the epidermal growth factor receptor is associated with disease progression, poor survival, poor response to therapy, and the development of resistance to therapy in many solid tumors. Cetuximab blocks the binding of natural ligands t...
متن کاملSuccessful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
Infusion reactions are serious complications associated with modern antibody therapy. In order to reduce the incidence and severity of such reactions, the newer generations of monoclonal antibodies contain less or no mouse-specific protein sequences. We describe the clinical course of a patient who experienced an infusion reaction following the administration of the chimeric epidermal growth fa...
متن کاملTargeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypers...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical journal of oncology nursing
دوره 12 3 شماره
صفحات -
تاریخ انتشار 2008